

**Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase – Interim Reporting**

With disclosure dated September 05, 2018, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the immediate beginning of a second tranche of up to USD 50 million under the share repurchase program originally announced on January 31, 2018.

The number of shares which have been bought back on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) within the framework of such tranche of the share repurchase program in the time period from September 17, 2018 until and including September 21, 2018 amounts to 191,745 shares.

Shares were bought back as follows:

<b>Date</b>	<b>Number of Shares acquired</b>	<b>Average Price (EUR)</b>	<b>Purchased Volume (EUR)</b>
17- September -2018	48,151	32.2106	1,550,972.60
18- September -2018	48,172	32.1967	1,550,979.43
19- September -2018	31,742	32.5745	1,033,979.78
20- September -2018	31,764	32.5523	1,033,991.26
21- September -2018	31,916	32.3972	1,033,989.04
<b>Total</b>	<b>191,745</b>	<b>32.3550</b>	<b>6,203,912.10</b>

The underlying individual trades are published on the website of QIAGEN N.V. (<http://corporate.qiagen.com/investor-relations/share-information/share-buyback>).

The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from September 05, 2018 until and including September 21, 2018 amounts to 471,026 shares.

The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.

Venlo, 25 September 2018

Managing Board

###

**Contacts:**

**QIAGEN**

**Investor Relations**

John Gilardi  
e-mail: [ir@qiagen.com](mailto:ir@qiagen.com)

+49 2103 29 11711

**Public Relations**

Dr. Thomas Theuringer  
e-mail: [pr@qiagen.com](mailto:pr@qiagen.com)

+49 2103 29 11826